According to the unaudited financial data for the financial year 2008, China Pharma achieved record high revenues. The Company's work to strengthen accounts receivable collection led to clear improvements in collection, and effective control of accounts receivable. The Company also realized record high positive cash flow in operating activity. The sales revenue improved by over 50% compared to the previous year, while the net income improved by over 35% compared to the previous year.
China Pharma's President and CEO, Ms.
The Company expects to announce more detailed information including
audited fourth quarter and full year 2008 results in a press release and
conference call to be scheduled in
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with
rapidly growing profit that develops, manufactures, and markets treatments for
a wide range of high incidence and high mortality conditions in
Safe Harbor Statement: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
For more information, please contact: China Pharma Holdings, Inc. Diana Huang Tel: +86-898-6681-1730 Email: hps@chinapharmaholdings.com The Ruth Group Sara Ephraim Tel: +1-646-536-7002 Email: sephraim@theruthgroup.com
SOURCE China Pharma Holdings, Inc.